Contrasting Evidence to Reimbursement Reality for Off-label use (OLU) of Drug Treatments in Cancer Care – Rationale and Design of the CEIT-OLU-project
Authors:
- Ak HerbrandAHAk Herbrand
- Am SchmittASAm Schmitt
- M BrielMBM Briel
- S DiemSDS Diem
- H EwaldHEH Ewald
- A HoogkamerAHA Hoogkamer
- M JoergerMJM Joerger
- Ka Mc CordKCKa Mc Cord
- U NovakUNU Novak
- S SricharoenchaiSSS Sricharoenchai
- Lg HemkensLHLg Hemkens
- B KasendaBKB Kasenda
Preprint
Abstract
Background: Off-label drug use (OLU) reflects a perceived unmet medical need, which is common in oncology. Cancer drugs are often highly expensive and their reimbursement is a challenge for many health care systems. OLU is frequently regulated by reimbursement restrictions. For evidence-based health care, treatment ought to be reimbursed if there is sufficient clinical evidence for treatment benefit independently of patient factors not related to the treatment indication. However, little is known about the reality of OLU reimbursement and its association with the underlying clinical evidence. Here we aim to investigate the relationship of reimbursement decisions with the underlying clinical evidence. Methods/Design: We extract patient characteristics and details on treatment and reimbursement of cancer drugs from over 3000 patients treated in three Swiss hospitals. We systematically search for clinical trial evidence on benefits associated with OLU in the most common indications. We will describe the prevalence of OLU in Switzerland and its reimbursement in cancer care, and use multivariable logistic regression techniques to investigate the association of approval/rejection of a reimbursement requests to the evidence on treatment effects and to further factors, including type of drug, molecular predictive markers and the health insurer. Discussion: Our study will provide a systematic overview and assessment of OLU and its reimbursement reality in Switzerland. We may provide a better understanding of the access to cancer care that is regulated by health insurers and we hope to identify factors that determine the level of evidence-based cancer care in a highly diverse Western health care system.Keywords
All Related Versions
- Published version: ESMO Open, 4 (6), e000596.
This publication has 15 references indexed in Scilit:
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)Annals of Oncology, 2014
- Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort studyEuropean Journal of Clinical Pharmacology, 2014
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2013
- Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trialThe Lancet Oncology, 2012
- Multiple imputation for missing data in epidemiological and clinical research: potential and pitfallsBMJ, 2009
- Regulating Off-Label Drug Use — Rethinking the Role of the FDANew England Journal of Medicine, 2008
- Recent developments in meta‐analysisStatistics in Medicine, 2007
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialThe Lancet, 2000
- Cumulative meta-analysis of clinical trials builds evidence for exemplary medical careJournal of Clinical Epidemiology, 1995